GlassScriptPhysician profile
Sandra Vazquez Diaz
NPI 1194110023
$3,210.24
in general payments reported to CMS, 2019-2025
27 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.08 · 2022: $566 · 2023: $901 · 2024: $653 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,565.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $391.75 | 2021-2025 | Wegovy, Sogroya |
| Tandem Diabetes Care, INC. | $348.20 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $301.08 | 2023-2025 | Dexcom G6 Transmitter |
| Tolmar, INC. | $283.44 | 2023-2025 | Fensolvi |
| Pfizer INC. | $283.11 | 2022-2025 | |
| Ascendis Pharma Endocrinology INC | $264.31 | 2022-2025 | Skytrofa |
| Abbvie INC. | $196.74 | 2021-2025 | Lupron Depot |
| Sanofi-Aventis U.S. LLC | $120.53 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $110.35 | 2022-2025 | Strensiq |
| Neurocrine Biosciences, INC. | $91.01 | 2024-2025 | |
| Biomarin Pharmaceutical INC. | $90.89 | 2021-2025 | Voxzogo 1.2mg |
| Eton Pharmaceuticals, INC. | $77.79 | 2023-2025 | Alkindi, Increlex, Khindivi |
| Tolmar Pharmaceuticals, INC. | $74.03 | 2022 | |
| Insulet Corporation | $66.49 | 2024-2025 | Omnipod |
| Sequel Med Tech, LLC | $61.93 | 2025 | Twiist |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $60.61 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Kyowa Kirin, INC. | $60.40 | 2023-2025 | Crysvita |
| Rhythm Pharmaceuticals, INC. | $58.01 | 2022-2025 | Imcivree |
| Endo Pharmaceuticals INC. | $53.07 | 2022-2023 | Supprelin |
| Mannkind Corporation | $50.00 | 2023 | Afrezza |
| Antares Pharma, INC. | $38.57 | 2022-2023 | Xyosted, Nocdurna, Tlando |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.01 | 2024 | Jardiance |
| Ipsen Biopharmaceuticals, INC | $25.22 | 2023 | |
| Zealand Pharma US, INC. | $21.33 | 2022 | |
| Rgh Enterprises LLC | $18.29 | 2024 | |
| Amneal Pharmaceuticals LLC | $15.40 | 2025 | Unithroid |
| Medtronic, INC. | $13.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Vazquez Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.